Landaas & Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Landaas & Company’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-600	Closed	-$57K	–	316
2018 Q2	$57K	Buy	+600	New	+$55.1K	0.05%	136
2018 Q1	–	Sell	-600	Closed	-$51K	–	312
2017 Q4	$51K	Hold	600	–	–	0.04%	147
2017 Q3	$52K	Buy	+600	New	+$48.1K	0.05%	145

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Landaas & Company's XBI Position: Q3 2018 in Review

Landaas & Company sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2018, closing a stake of 600 shares — an estimated $57K sold.

Landaas & Company first reported a position in XBI in Q3 2017 and held it in 3 quarters. The position peaked at $57K in Q2 2018. 432 funds tracked by Wall St. Rank hold XBI as of Q3 2018.

Landaas & Company reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2018 after selling out during the quarter.
Landaas & Company sold 600 State Street SPDR S&P Biotech ETF shares in Q3 2018, an estimated $57K.
Landaas & Company first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and held it in 3 quarters.
Landaas & Company's State Street SPDR S&P Biotech ETF position peaked at $57K in Q2 2018.
432 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2018.

Based on Landaas & Company's 13F filing for Q3 2018, filed 14 Nov 2018.